Corcept Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Corcept Therapeutics has a total shareholder equity of $506.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $621.5M and $114.8M respectively. Corcept Therapeutics's EBIT is $107.3M making its interest coverage ratio -6.2. It has cash and short-term investments of $368.2M.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -6.2x |
| Cash | US$368.22m |
| Equity | US$506.71m |
| Total liabilities | US$114.81m |
| Total assets | US$621.52m |
Recent financial health updates
No updates
Recent updates
With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For
Apr 15
We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit
Feb 22Corcept Therapeutics: Key Catalysts Ahead
Feb 19After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar
Dec 23Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price
Nov 07Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?
Jun 23Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)
Feb 16Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today
Jan 11Corcept Therapeutics starts phase 2 trial of its ALS treatment
Oct 11Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?
Sep 27Corcept extends distribution agreement for Cushing’s syndrome drug
Sep 23Corcept Therapeutics: A Status Check
Sep 06Corcept cut to Hold at Truist on balanced risk-reward setup
Aug 01Corcept Therapeutics begins phase 3 trial of relacorilant for ovarian cancer
Jun 29I Ran A Stock Scan For Earnings Growth And Corcept Therapeutics (NASDAQ:CORT) Passed With Ease
Jun 09Is Now The Time To Put Corcept Therapeutics (NASDAQ:CORT) On Your Watchlist?
Feb 23Financial Position Analysis
Short Term Liabilities: CORT's short term assets ($458.6M) exceed its short term liabilities ($104.5M).
Long Term Liabilities: CORT's short term assets ($458.6M) exceed its long term liabilities ($10.3M).
Debt to Equity History and Analysis
Debt Level: CORT is debt free.
Reducing Debt: CORT had no debt 5 years ago.
Debt Coverage: CORT has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CORT has no debt, therefore coverage of interest payments is not a concern.